Drug General Information
Drug ID	D00WME
Former ID	DCL000504
Drug Name	Conatumumab
Drug Type	Monoclonal antibody
Indication	Colorectal cancer [ICD9: 153, 154; ICD10:C18-C21]		Phase 2	[523418]
Company	Amgen; Takeda
Structure		Download 2D MOL 3D MOL
Formula	C32H39ClN6O7S
PubChem Compound ID	9831419
Target and Pathway
Target(s)	Tumor necrosis factor receptor superfamily member 10B	Target Info	Agonist	[525342], [550250]
KEGG Pathway	Cytokine-cytokine receptor interaction
	p53 signaling pathway
	Apoptosis
	Natural killer cell mediated cytotoxicity
	Measles
	Influenza A
NetPath Pathway	TCR Signaling Pathway
	TNFalpha Signaling Pathway
PANTHER Pathway	Apoptosis signaling pathway
	p53 pathway
Pathway Interaction Database	TRAIL signaling pathway
	Direct p53 effectors
	Caspase Cascade in Apoptosis
Reactome	Ligand-dependent caspase activation
	Regulation by c-FLIP
	RIPK1-mediated regulated necrosis
	CASP8 activity is inhibited
	Dimerization of procaspase-8
	TRAIL signaling
WikiPathways	DNA Damage Response
	Apoptosis-related network due to altered Notch3 in ovarian cancer
	Apoptosis
	miR-targeted genes in squamous cell - TarBase
	miR-targeted genes in muscle cell - TarBase
	miR-targeted genes in lymphocytes - TarBase
	miR-targeted genes in epithelium - TarBase
	Extrinsic Pathway for Apoptosis
	Apoptosis Modulation and Signaling
	miRNA Regulation of DNA Damage Response
References
Ref 523418	ClinicalTrials.gov (NCT01327612) Open Label Extension Study of Conatumumab and AMG 479. U.S. National Institutes of Health.
Ref 525342	ClinicalTrials.gov (NCT00534027) Amgen. Report of Amgen. January 22, 2009.
Ref 550250	Clinical pipeline report, company report or official report of Amgen (2009).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.